Brimonidine Tartrate + Timolol MaleateThird Party Manufacturing in India

Brimonidine Tartrate + Timolol Maleate works through a dual mechanism of action where brimonidine reduces aqueous humor production and increases uveoscleral outflow, while timolol selectively decreases fluid secretion within the ciliary processes. They bind to alpha-2 and beta receptors respectively to help the body rapidly lower intraocular pressure. Unlike single-agent therapies, this combination provides an enhanced additive effect, optimizing patient compliance. It is highly effective and well-tolerated for long-term pressure regulation.

Therapeutic Uses

• Glaucoma Management: Prescribed for the reduction of elevated intraocular pressure in patients with open-angle glaucoma who are insufficiently controlled on mono-therapy.
• Ocular Hypertension: Indicated for targeted treatment of severe ocular hypertension requiring multi-mechanism intervention.

Why Manufacturers Choose Brimonidine Tartrate + Timolol Maleate

Brimonidine Tartrate + Timolol Maleate third party manufacturing in India is a major segment within prescription ophthalmology due to its high clinical efficacy and medical preference over monotherapies. Celesta provides professional sourcing through partner facilities that are WHO-GMP certified, guaranteeing compliance with global regulatory standards. Offering this combination allows distributors to expand into high-value chronic care prescription lines under trusted WHO-GMP manufacturing setups.